Phase II InnoCare data spell competition in psoriasis

10 October 2024

Beijing’s InnoCare Pharma (HKEX: 09969) has announced encouraging Phase II results for its novel TYK2 inhibitor, ICP-488, aimed at treating moderate-to-severe plaque psoriasis.

The data signal that ICP-488 could compete with other leading TYK2 inhibitors in development, including Bristol Myers Squibb’s (NYSE: BMY) Sotyktu (deucravacitinib) and Takeda’s (TSE: 4502) TAK-279, which was acquired from Nimbus Therapeutics in a multi-billion dollar deal.

The study revealed that after 12 weeks, ICP-488 hit key efficacy goals. In the 6mg and 9mg dosing groups, 77.3% and 78.6% of patients achieved a particular target, compared to 11.6% in the placebo group.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical